114870-03-0

114870-03-0 structure

Name	fondaparinux sodium
Synonyms	α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), decasodium salt Decasodium methyl 2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-β-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-2- O-sulfonato-α-L-idopyranuronosyl-(1->;4)-2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranoside α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10) Fondaparin sodium Arixtra Fondaparinux sodium α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4 )-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10) Fondaparinux (sodium)

Description	Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Factor Xa Research Areas >> Cardiovascular Disease
Target	Factor Xa[1]
In Vitro	Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs)[2].
In Vivo	Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation[1].
References	[1]. Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7. [2]. Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.

RIDADR	NONH for all modes of transport